Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statement of Changes in Stockholders' Equity

v3.26.3
Condensed Consolidated Statement of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Non-Controlling Interests
Total
Balance at Dec. 31, 2024 $ 3 $ 28 $ 763,573 $ (740,867) $ (24,381) $ (1,644)
Balance (in shares) at Dec. 31, 2024 3,427,138 27,908,839        
Stock-based compensation expense     26,280     26,280
Issuance of common stock related to equity plans   $ 1 (1)      
Issuance of common stock related to equity plans (in shares)   1,278,005        
Issuance of common stock under ESPP     43     43
Issuance of common stock under ESPP (in shares)   35,546        
Issuance of stock for equity offerings, net   $ 1 1,008     1,009
Issuance of stock for equity offerings, net (in shares)   539,563        
Redemption of partner company preferred shares     (265)     (265)
Partner companies' offerings, net and warrant exercises     61,238     61,238
Partner companies' at-the-market offering, net     13,631     13,631
Issuance of common stock under partner company's ESPP     217     217
Partner company's dividends declared and paid     (498)     (498)
Exercise of warrants   $ 1 2,279     2,280
Exercise of warrants (in shares)   1,355,582        
Partner company's exercise of options for cash     343     343
Shares withheld related to net settlement of warrants   (112,365)        
Deconsolidation of subsidiary non-controlling interests         (9,931) (9,931)
Non-controlling interest in partner companies     (81,905)   81,905  
Attributable to non-controlling interests         (38,270) (38,270)
Net income (loss) attributable to common stockholders       10,752   10,752
Balance at Sep. 30, 2025 $ 3 $ 31 785,943 (730,115) 9,323 65,185
Balance (in shares) at Sep. 30, 2025 3,427,138 31,005,170        
Balance at Jun. 30, 2025 $ 3 $ 30 779,856 (735,965) (6,541) 37,383
Balance (in shares) at Jun. 30, 2025 3,427,138 29,752,775        
Stock-based compensation expense     3,197     3,197
Issuance of common stock related to equity plans (in shares)   106,378        
Partner company's warrant exercises     7,144     7,144
Partner companies' at-the-market offering, net     6,891     6,891
Issuance of common stock under partner company's ESPP     118     118
Partner company's dividends declared and paid     (166)     (166)
Exercise of warrants   $ 1 1,687     1,688
Exercise of warrants (in shares)   1,258,382        
Partner company's exercise of options for cash     103     103
Shares withheld related to net settlement of warrants   (112,365)        
Non-controlling interest in partner companies     (12,887)   12,887  
Attributable to non-controlling interests         2,977 2,977
Net income (loss) attributable to common stockholders       5,850   5,850
Balance at Sep. 30, 2025 $ 3 $ 31 785,943 (730,115) 9,323 65,185
Balance (in shares) at Sep. 30, 2025 3,427,138 31,005,170        
Balance at Dec. 31, 2025 $ 3 $ 31 783,891 (734,052) 12,310 62,183
Balance (in shares) at Dec. 31, 2025 3,427,138 31,364,094        
Stock-based compensation expense     6,782     6,782
Issuance of common stock related to equity plans   $ 1 (1)      
Issuance of common stock related to equity plans (in shares)   1,397,885        
Issuance of common stock under ESPP     74     74
Issuance of common stock under ESPP (in shares)   34,087        
Exchange of partner company preferred shares     (165)     (165)
Issuance of common stock under partner company's ESPP     223     223
Partner company's dividends declared and paid     (23,199)     (23,199)
Exercise of warrants   $ 1 1,217     1,218
Exercise of warrants (in shares)   694,296        
Partner company's exercise of options for cash     275     275
Non-controlling interest in partner companies     20,737   (20,737)  
Attributable to non-controlling interests         25,451 25,451
Net income (loss) attributable to common stockholders       104,060   104,060
Issuance of partner company's common shares for research and development expenses     107     107
Issuance of subsidiary warrants for contingent liability     12     12
Balance at Sep. 30, 2026 $ 3 $ 33 789,953 (629,992) 17,024 177,021
Balance (in shares) at Sep. 30, 2026 3,427,138 33,490,362        
Balance at Jun. 30, 2026 $ 3 $ 33 788,251 (624,147) 41,946 206,086
Balance (in shares) at Jun. 30, 2026 3,427,138 33,311,012        
Stock-based compensation expense     2,149     2,149
Issuance of common stock related to equity plans (in shares)   179,350        
Issuance of common stock under partner company's ESPP     75     75
Partner company's dividends declared and paid     (23,199)     (23,199)
Partner company's exercise of options for cash     45     45
Non-controlling interest in partner companies     22,513   (22,513)  
Attributable to non-controlling interests         (2,409) (2,409)
Net income (loss) attributable to common stockholders       (5,845)   (5,845)
Issuance of partner company's common shares for research and development expenses     107     107
Issuance of subsidiary warrants for contingent liability     12     12
Balance at Sep. 30, 2026 $ 3 $ 33 $ 789,953 $ (629,992) $ 17,024 $ 177,021
Balance (in shares) at Sep. 30, 2026 3,427,138 33,490,362